Publications
Twelve papers, two preprints, one question
Author position is given for every entry, and each carries a note on what it showed and what my role was. Five are first-author papers, across two research systems and two supervisors. The complete record is on ORCID.
-
2026The writable window: cell-cycle exit limits division-coupled DNA recorders in human cortical organoidsbioRxiv · preprint in preparationSole author — conceived, modelled, analysed and wrote it
A model of differentiating human cortical progenitors coupled to a prime-editing array, asking what this class of recorder can resolve over a 150-day differentiation. Recording capacity is spent early — half of it before day 27. A signal-responsive channel needs a dynamic range near 1,700, against the 11.5- to 22.6-fold of channels characterised to date. Editing rate, not array length, is the binding constraint. Simulator, code and results released openly.
-
2026ACS Chemical Neuroscience 17(16), 3048–3057Second author — co-conceptualisation, design, methodology, implementation, project administration
The study was my idea and I initiated the collaboration with the electrophysiologists, then stepped back from first authorship so the paper could serve a doctoral defence. I was solely responsible for the organoid differentiation the study rests on: in a paper whose headline is electrophysiology, owning the differentiation means owning the substrate. It is the platform the current programme depends on.
-
2025Neurochemistry International 190, 106056Second author on the listing, first author in substance — conceptualisation, methodology, investigation, formal analysis, validation, visualisation, project administration, writing
I stepped back so the paper could count for the postdoc ahead of me. I ran the human cell work and reconciled it against the embryonic arm. A drug-specific structural effect reproduces across the two systems, with miR-92 emerging as a molecular bridge between them. Carrying one question across unrelated model systems is the central methodological demand of the current programme.
-
2023Neurochemistry International 169, 105571First author
I built and electrophysiologically validated a pure human neuronal culture, then designed and ran the exposure series. The canonical molecular readout moved in the reassuring direction while the structural readout moved in the concerning one — for one drug and not the other. A single-endpoint study would have reached the opposite conclusion.
-
2022Heliyon 8(8), e10291Second author — a clinical genomics collaboration outside both my doctoral and postdoctoral environments
I analysed and interpreted the genomic instability and amplification data, nominated and excluded the therapeutic targets, and wrote the manuscript. Evidence that I initiate and carry collaborations of my own choosing.
-
2022Toxicology and Applied Pharmacology 449, 116130Contributing author — differentiated the human NTera2 neurons the study used and analysed that arm
A cytoskeletal mechanism for an epidemiological signal, in a human and a chicken model at once. It is the association-to-mechanism move the current programme sets out to industrialise.
-
2022Neurotoxicology and Teratology 90, 107057First author — conceived, executed and wrote the study
Two drugs with different morphological signatures converge on a single developmental transcription factor. The result names a developmental programme rather than a day of exposure — the inference the current work generalises from one gene to cell state.
-
2021Journal of Pharmacological and Toxicological Methods 112, 107105First author — designed the study, performed all in ovo dosing and timed sampling, interfaced the bioanalysis
Drugs reach the developing brain within minutes at clinically relevant concentrations, and how far they get depends on developmental stage. My own methodological contribution, and the direct precedent for insisting that exposure be resolved by developmental stage rather than by dose alone.
-
2021Toxicology Letters 338, 85–96Contributing author — differentiated the PC12 neurons, analysed that arm and edited the manuscript
A defined mixture modelled on Scandinavian blood concentrations enhanced rather than inhibited neurite outgrowth — developmental neurotoxicity does not always look like cell death. Direct experience of dose realism, which the current design turns into an internal-dose anchoring requirement.
-
2021
-
2019Neuroscience and Behavioral Physiology 49(6), 765–772Second author
Neural stem cells from seizure-prone animals proliferated less and differentiated faster than controls — aberrant neurogenesis as a genetically determined cause rather than a consequence of epilepsy.
-
2018Neuroscience Letters 684, 6–12First author — in the research line I began before my doctorate
Blocking ERK1/2 raises dopamine release: the cascade that drives differentiation also restrains transmitter release, and the direction of a drug effect depends on the state the cell is in. This is the seed of the current hypothesis.
-
2017Russian Journal of Genetics: Applied Research 7(3), 217–225Contributing author
-
2016Neuroscience and Behavioral Physiology 46(5), 559–565First author of two — from a research system and a supervisor entirely separate from my doctoral work
Places p53 upstream of cRaf at a defined position in the cascade controlling neuronal differentiation. The earliest point in one continuous question, and evidence of an independent mechanistic line predating Oslo.